News

Aurobindo Pharma (Aurobindo) has received the final approval for Risperidone Oral Solution 1mg/ml (ANDA No. 78-452) from the FDA. Risperidone Oral Solution 1mg/ml is generic equivalent to Risperdal

Can-Fite BioPharma (Can-Fite) has reported that its 75-patient phase II clinical study with CF101 to treat patients with moderate to severe Psoriasis has successfully met its primary objectives.

The FDA has notified Cell Therapeutics (CTI) that a Prescription Drug User Fee Act (PDUFA) action date of April 23, 2010 under standard review, has been established regarding

Biogen Idec has submitted a proposal to the Board of Directors of Facet Biotech Corporation to acquire all of the outstanding shares of Facet for $14.50 per share

Karolinska Development has announced that one of its portfolio companies, Dilafor, has concluded an extensive clinical study of its candidate drug, tafoxiparin, a new drug substance for the

Terumo and Takeda have announced that the two companies will initiate the co-promotion of ethical narcotic formulations in October, which is manufactured and marketed by Takeda in Japan.

Hard to Treat Diseases (HTDC) has announced that its China based subsidiary Mellow Hope, has finished the clinical trial of Cerebroprotein Hydrolysate for Injection (NUTRIPROTEIN) in India. The

Human Genome Sciences (HGS) has reported the publication of the results of primary endpoint of two pivotal phase 3 clinical trials of Benlysta (belimumab) in serologically active patients

Spectrum Pharmaceuticals (Spectrum) has received FDA approval for Zevalin for an expanded label for the treatment of patients with previously untreated follicular non-Hodgkin’s Lymphoma (NHL), who achieve a